Description of Business and Significant Accounting Policies - Additional Information (Detail) € in Millions	1 Months Ended			3 Months Ended
	Jan. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Apr. 30, 2021 USD ($)	Mar. 31, 2024 USD ($) Segment	Mar. 31, 2024 EUR (€)	Dec. 31, 2023 USD ($)	Aug. 31, 2019 USD ($)	Jul. 01, 2013 USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit				$ (3,218,777,000)		$ (3,229,407,000)
Cash and cash equivalents				193,272,000		238,480,000
Short-term investments				107,457,000		56,619,000
Long-term investments				3,726,000		7,155,000
Financing liability				$ 104,100,000		104,100,000
Percentage of future royalties				1.00%
Number of operating segment | Segment				1
Loss on purchase commitments | €					€ 58.9
Insulin
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Loss on purchase commitments				$ 62,700,000		64,800,000
Tyvaso DPI
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of royalty on net sales				10.00%
Percentage of royalty on net revenue				10.00%
Percentage of future royalties				9.00%
Maximum | AFREZZA product sales
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months				12 months
Minimum | AFREZZA product sales
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months				6 months
Convertible Promissory Note | Thirona Bio, Inc.
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount				$ 8,000,000
Purchase of available-for-sale securities	$ 5,000,000.0	$ 3,000,000
Interest rate		6.00%
MidCap Credit Facility
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount				$ 28,300,000		$ 33,300,000
Principal prepayment against outstanding term loans			$ 10,000,000.0
MidCap Credit Facility | Tranche Three
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Amount available under credit facility							$ 60,000,000
Milestone Rights Liability | Deerfield
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Contingent liability remain payable								$ 55,000,000
Milestone Rights Liability | Maximum | Deerfield
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Contingent liability for milestone payments								$ 90,000,000